文献速递儿童内分泌与遗传代谢

Vosoritide 治疗 3-59 月龄软骨发育不全儿童:2 期随机对照试验

Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Child Adolesc Health · 2023-11-18

这项多国、随机、双盲、安慰剂对照的 2 期试验纳入 75 例 60 月龄以下经基因确诊的软骨发育不全儿童,评估每日皮下注射 vosoritide 52 周的安全性与身高 Z 评分变化。

要点

  • Vosoritide 在 3-59 月龄软骨发育不全儿童中 52 周耐受性良好,不良事件多为短暂注射部位反应。
  • 严重不良事件发生率 vosoritide 组 7%(3 例),安慰剂组 19%(6 例)。

核心结论

  • 3-59 月龄软骨发育不全儿童接受 vosoritide 治疗 52 周,不良事件总体轻微,身高 Z 评分较基线有所增加。

研究设计与样本

  • 多国、随机、双盲、安慰剂对照 2 期试验,在澳大利亚、日本、英国和美国 16 家医院开展。
  • 纳入 75 例 60 月龄以下经基因检测确诊的软骨发育不全儿童,按筛查年龄分 3 个连续队列(24-59 月龄、6-23 月龄、0-5 月龄)。
  • 每个队列先设哨兵接受 vosoritide 确定每日剂量,其余按 1:1 随机接受每日皮下注射 vosoritide 或安慰剂 52 周。
  • 第一主要结局为安全性与耐受性(至少接受一剂者),第二主要结局为 52 周身高 Z 评分较基线变化(全部随机化者)。

主要发现

  • 2018 年 5 月 13 日至 2021 年 3 月 1 日共招募 75 例参与者,37 例(49%)为女性。
  • 11 例为哨兵,32 例随机接受 vosoritide,32 例随机接受安慰剂。
  • Vosoritide 组 1 例死亡退出,安慰剂组 1 例撤回退出。
  • 严重不良事件 vosoritide 组 3 例(7%),安慰剂组 6 例(19%)。

临床怎么用

  • 对于 3-59 月龄软骨发育不全儿童,vosoritide 每日皮下注射 52 周总体耐受性良好,不良事件以短暂注射部位反应为主。
  • 身高 Z 评分改善的置信区间包含 0,需结合后续研究判断临床意义。

局限性

  • 原文未报告样本量计算依据或统计效能。
  • 原文未报告身高 Z 评分变化的 P 值。
  • 原文未报告长期生长结局或最终成年身高数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vosoritide is a recombinant C-type natriuretic peptide analogue that increases annualised growth velocity in children with achondroplasia aged 5-18 years. We aimed to assess the safety and efficacy of vosoritide in infants and children younger than 5 years. METHODS: This double-blind, randomised, placebo-controlled, phase 2 trial was done in 16 hospitals across Australia, Japan, the UK, and the USA. Children younger than 60 months with a clinical diagnosis of achondroplasia confirmed by genetic testing and who had completed a baseline growth study or observation period were enrolled into one of three sequential cohorts based on age at screening: 24-59 months (cohort 1); 6-23 months (cohort 2); and 0-5 months (cohort 3). Each cohort included sentinels who received vosoritide to determine appropriate daily drug dose, with the remainder randomly assigned (1:1) within each age stratum (except in Japan, where participants were randomly assigned within each cohort) to receive daily subcutaneous injections of vosoritide (30·0 μg/kg for infants aged 0-23 months; 15·0 μg/kg for children aged 24-59 months) or placebo for 52 weeks. Participants, caregivers, investigators, and the sponsor were masked to treatment assignment. The first primary outcome was safety and tolerability, assessed in all participants who received at least one study dose. The second primary outcome was change in height Z score at 52 weeks from baseline, analysed in all randomly assigned participants. This trial is registered with EudraCT, 2016-003826-18, and ClinicalTrials.gov, NCT03583697. FINDINGS: Between May 13, 2018, and March 1, 2021, 75 participants were recruited (37 [49%] females). 11 were assigned as sentinels, whereas 32 were randomly assigned to receive vosoritide and 32 placebo. Two participants discontinued treatment and the study: one in the vosoritide group (death) and one in the placebo group (withdrawal). Adverse events occurred in all 75 (100%) participants (annual rate 204·5 adverse events per patient in the vosoritide group and 73·6 per patient in the placebo group), most of which were transient injection-site reactions and injection-site erythema. Serious adverse events occurred in three (7%) participants in the vosoritide group (decreased oxygen saturation, respiratory syncytial virus bronchiolitis and sudden infant death syndrome, and pneumonia) and six (19%) participants in the placebo group (petit mal epilepsy, autism, gastroenteritis, vomiting and parainfluenza virus infection, respiratory distress, and skull fracture and otitis media). The least-squares mean difference for change from baseline in height Z score between the vosoritide and placebo groups was 0·25 (95% CI -0·02 to 0·53). INTERPRETATION: Children with achondroplasia aged 3-59 months receiving vosoritide for 52 weeks had a mild adverse event profile and gain in the change in height Z score from baseline. FUNDING: BioMarin Pharmaceutical.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2023. PMID: 37984383. doi:10.1016/S2352-4642(23)00265-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。